サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1702018

モノクローナル抗体（mAbs）市場：生産方法別、由来別、適応症別、最終用途別、地域別、2025-2033年

Monoclonal Antibodies Market Report by Production Method, Source, Indication, End Use, and Region 2025-2033

出版日
発行
IMARC
ページ情報
英文 147 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.69円
モノクローナル抗体（mAbs）市場：生産方法別、由来別、適応症別、最終用途別、地域別、2025-2033年
出版日: 2025年04月01日
発行: IMARC
ページ情報: 英文 147 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

モノクローナル抗体（mAbs）市場の世界市場規模は2024年に2,358億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに4,107億米ドルに達し、2025年から2033年にかけて6.04%の成長率（CAGR）を示すと予測しています。がん、自己免疫疾患、感染症などの慢性疾患の有病率の上昇、二重特異性抗体や抗体薬物複合体（ADC）のような技術革新、高齢者人口の増加、腫瘍学や免疫療法の拡大などが市場の成長を後押ししています。

モノクローナル抗体（mAbs）は、不要な細胞に対する免疫系の攻撃を強化、修正、回復、模倣することができる代用抗体の役割を果たすために使用される実験室で生産されるタンパク質です。免疫系を強化することによって、がん細胞を検出し、標的にして破壊するために利用されます。また、がん細胞と細胞増殖を促進するタンパク質との結合を阻害するためにも使用されます。さらに、免疫系細胞ががん細胞に対して効率的に働くためのタンパク質の形成を阻害します。これに加えて、mAbsは放射線治療をがん細胞に直接運び、健康な細胞への放射線の影響を最小限に抑えます。

モノクローナル抗体（mAbs）市場動向：

現在、がん、心臓病、脳卒中、糖尿病、関節炎などの慢性疾患の有病率の増加が市場を牽引する重要な要因の一つとなっています。これに加え、主要メーカーはアルツハイマー病、ハンチントン病、パーキンソン病、レビー小体病などの神経変性疾患の治療薬としてより優れたmAb製剤を導入するため、研究開発（R&D）活動に幅広く投資しています。また、顧客基盤を拡大するために様々なマーケティング戦略にも注力しており、これが市場の成長に寄与しています。加えて、がん細胞、免疫抑制、免疫調節分子など様々な抗原を治療するためのヒト化mAbに対する需要の高まりは、業界の投資家に有利な成長機会を提供しています。これとは別に、世界中でがんを治療するためのコスト効率の高いバイオシミラーmAbsの需要が増加しています。これは、急成長するヘルスケア産業とともに、市場の成長を後押ししています。さらに、次世代シーケンシングのような様々な遺伝子プラットフォームにおける技術的進歩が、市場見通しに明るい兆しをもたらしています。さらに、世界中でmAbs生産における高度な遺伝子工学技術の採用が増加しています。これは、mAb治療の利点に関する大衆の意識の高まりと相まって、市場の成長を後押ししています。

本レポートで扱う主な質問

  • 2024年の世界のモノクローナル抗体（mAbs）市場の市場規模は？
  • 2025-2033年の世界のモノクローナル抗体（mAbs）市場の予想成長率は？
  • 世界のモノクローナル抗体（mAbs）市場を牽引する主要因は何か？
  • 世界のモノクローナル抗体（mAbs）市場に対するCOVID-19の影響は？
  • 世界のモノクローナル抗体（mAbs）市場における生産方法別内訳は？
  • 世界のモノクローナル抗体（mAbs）市場の由来別内訳は？
  • 世界のモノクローナル抗体（mAbs）市場の適応別内訳は？
  • 世界のモノクローナル抗体（mAbs）市場の最終用途別内訳は？
  • 世界のモノクローナル抗体（mAbs）市場における主要地域は？
  • 世界のモノクローナル抗体（mAbs）市場における主要プレイヤー／企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のモノクローナル抗体（mAbs）市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：生産方法別

  • In vivo
  • In vitro（体外）

第7章 市場内訳：由来別

  • マウス
  • キメラ
  • ヒト化
  • ヒト

第8章 市場内訳：適応症別

  • がん
  • 自己免疫疾患
  • 炎症性疾患
  • 感染症
  • その他

第9章 市場内訳：最終用途別

  • 病院
  • 研究機関
  • その他

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋地域
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場内訳：国別

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • AbbVie Inc.
    • Amgen Inc.
    • Biogen Inc.
    • F. Hoffmann-La Roche AG
    • GSK plc
    • Johnson & Johnson
    • Merck KGaA
    • Novartis AG
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Sanofi S.A.
    • Thermo Fisher Scientific Inc.
図表

List of Figures

  • Figure 1: Global: Monoclonal Antibodies Market: Major Drivers and Challenges
  • Figure 2: Global: Monoclonal Antibodies Market: Sales Value (in Billion USD), 2019-2024
  • Figure 3: Global: Monoclonal Antibodies Market Forecast: Sales Value (in Billion USD), 2025-2033
  • Figure 4: Global: Monoclonal Antibodies Market: Breakup by Production Method (in %), 2024
  • Figure 5: Global: Monoclonal Antibodies Market: Breakup by Source (in %), 2024
  • Figure 6: Global: Monoclonal Antibodies Market: Breakup by Indication (in %), 2024
  • Figure 7: Global: Monoclonal Antibodies Market: Breakup by End Use (in %), 2024
  • Figure 8: Global: Monoclonal Antibodies Market: Breakup by Region (in %), 2024
  • Figure 9: Global: Monoclonal Antibodies (In Vivo) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 10: Global: Monoclonal Antibodies (In Vivo) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 11: Global: Monoclonal Antibodies (In Vitro) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 12: Global: Monoclonal Antibodies (In Vitro) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 13: Global: Monoclonal Antibodies (Murine) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 14: Global: Monoclonal Antibodies (Murine) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 15: Global: Monoclonal Antibodies (Chimeric) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 16: Global: Monoclonal Antibodies (Chimeric) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 17: Global: Monoclonal Antibodies (Humanized) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 18: Global: Monoclonal Antibodies (Humanized) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 19: Global: Monoclonal Antibodies (Human) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 20: Global: Monoclonal Antibodies (Human) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 21: Global: Monoclonal Antibodies (Cancer) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 22: Global: Monoclonal Antibodies (Cancer) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 23: Global: Monoclonal Antibodies (Autoimmune Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 24: Global: Monoclonal Antibodies (Autoimmune Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 25: Global: Monoclonal Antibodies (Inflammatory Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 26: Global: Monoclonal Antibodies (Inflammatory Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 27: Global: Monoclonal Antibodies (Infectious Diseases) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 28: Global: Monoclonal Antibodies (Infectious Diseases) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 29: Global: Monoclonal Antibodies (Other Indications) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 30: Global: Monoclonal Antibodies (Other Indications) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 31: Global: Monoclonal Antibodies (Hospitals) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 32: Global: Monoclonal Antibodies (Hospitals) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 33: Global: Monoclonal Antibodies (Research Institutes) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 34: Global: Monoclonal Antibodies (Research Institutes) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 35: Global: Monoclonal Antibodies (Other End Uses) Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 36: Global: Monoclonal Antibodies (Other End Uses) Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 37: North America: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 38: North America: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 39: United States: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 40: United States: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 41: Canada: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 42: Canada: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 43: Asia-Pacific: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 44: Asia-Pacific: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 45: China: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 46: China: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 47: Japan: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 48: Japan: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 49: India: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 50: India: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 51: South Korea: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 52: South Korea: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 53: Australia: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 54: Australia: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 55: Indonesia: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 56: Indonesia: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 57: Others: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 58: Others: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 59: Europe: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 60: Europe: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 61: Germany: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 62: Germany: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 63: France: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 64: France: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 65: United Kingdom: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 66: United Kingdom: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 67: Italy: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 68: Italy: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 69: Spain: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 70: Spain: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 71: Russia: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 72: Russia: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 73: Others: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 74: Others: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 75: Latin America: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 76: Latin America: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 77: Brazil: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 78: Brazil: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 79: Mexico: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 80: Mexico: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 81: Others: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 82: Others: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 83: Middle East and Africa: Monoclonal Antibodies Market: Sales Value (in Million USD), 2019 & 2024
  • Figure 84: Middle East and Africa: Monoclonal Antibodies Market: Breakup by Country (in %), 2024
  • Figure 85: Middle East and Africa: Monoclonal Antibodies Market Forecast: Sales Value (in Million USD), 2025-2033
  • Figure 86: Global: Monoclonal Antibodies Industry: SWOT Analysis
  • Figure 87: Global: Monoclonal Antibodies Industry: Value Chain Analysis
  • Figure 88: Global: Monoclonal Antibodies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Monoclonal Antibodies Market: Key Industry Highlights, 2024 and 2033
  • Table 2: Global: Monoclonal Antibodies Market Forecast: Breakup by Production Method (in Million USD), 2025-2033
  • Table 3: Global: Monoclonal Antibodies Market Forecast: Breakup by Source (in Million USD), 2025-2033
  • Table 4: Global: Monoclonal Antibodies Market Forecast: Breakup by Indication (in Million USD), 2025-2033
  • Table 5: Global: Monoclonal Antibodies Market Forecast: Breakup by End Use (in Million USD), 2025-2033
  • Table 6: Global: Monoclonal Antibodies Market Forecast: Breakup by Region (in Million USD), 2025-2033
  • Table 7: Global: Monoclonal Antibodies Market: Competitive Structure
  • Table 8: Global: Monoclonal Antibodies Market: Key Players
目次
Product Code: SR112025A6278

The global monoclonal antibodies market size reached USD 235.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 410.7 Billion by 2033, exhibiting a growth rate (CAGR) of 6.04% during 2025-2033. The rising prevalence of chronic disorders such as cancer, autoimmune disorders, and infectious diseases, innovations like bispecific antibodies and antibody-drug conjugates (ADCs), increasing geriatric population, and the expansion in oncology and immunotherapy are propelling the market growth.

Monoclonal antibodies (mAbs) are laboratory-produced proteins used to serve as substitute antibodies that can enhance, modify, restore, and mimic the attack of the immune system on unwanted cells. They are utilized for detecting and targeting cancer cells for destruction by enhancing the immune system. They are also employed to block the connection between a cancer cell and proteins that promote cell growth. In addition, they prevent the formation of proteins for enabling immune system cells to work efficiently against cancer cells. Besides this, mAbs transport the radiation treatment directly to cancer cells and minimize the effect of radiation on healthy cells

Monoclonal Antibodies Market Trends:

At present, the growing prevalence of chronic diseases, such as cancer, heart disease, stroke, diabetes, and arthritis, represents one of the key factors driving the market. Besides this, leading manufacturers are extensively investing in research and development (R&D) activities to introduce enhanced mAb drugs for treating neurodegenerative diseases, such as Alzheimer's, Huntington's, Parkinson's, and Lewy body diseases. They are also focusing on various marketing strategies to expand their customer base, which is contributing to the growth of the market. In addition, the increasing demand for humanized mAbs to treat various antigens, such as cancer cells, immunosuppression, and immunomodulatory molecules, are offering lucrative growth opportunities to industry investors. Apart from this, there is a rise in the demand for cost-efficient biosimilar mAbs to treat cancer across the globe. This, along with the burgeoning healthcare industry, is propelling the growth of the market. Moreover, technological advancements in various genetic platforms, such as next-generation sequencing, is offering a positive market outlook. Additionally, there is an increase in the employment of advanced genetic engineering technology in mAbs production around the world. This, coupled with the rising awareness among the masses about the benefits of mAb therapy, is bolstering the market growth.

Key Market Segmentation:

Breakup by Production Method:

  • In Vivo
  • In Vitro

Breakup by Source:

  • Murine
  • Chimeric
  • Humanized
  • Human

Breakup by Indication:

  • Cancer
  • Autoimmune Diseases
  • Inflammatory Diseases
  • Infectious Diseases
  • Others

Breakup by End Use:

  • Hospitals
  • Research Institutes
  • Others

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being AbbVie Inc., Amgen Inc., Biogen Inc., F. Hoffmann-La Roche AG, GSK plc, Johnson & Johnson, Merck KGaA, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A. and Thermo Fisher Scientific Inc.

Key Questions Answered in This Report

  • 1.What was the size of the global monoclonal antibodies market in 2024?
  • 2.What is the expected growth rate of the global monoclonal antibodies market during 2025-2033?
  • 3.What are the key factors driving the global monoclonal antibodies market?
  • 4.What has been the impact of COVID-19 on the global monoclonal antibodies market?
  • 5.What is the breakup of the global monoclonal antibodies market based on the production method?
  • 6.What is the breakup of the global monoclonal antibodies market based on the source?
  • 7.What is the breakup of the global monoclonal antibodies market based on the indication?
  • 8.What is the breakup of the global monoclonal antibodies market based on the end use?
  • 9.What are the key regions in the global monoclonal antibodies market?
  • 10.Who are the key players/companies in the global monoclonal antibodies market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Monoclonal Antibodies Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Production Method

  • 6.1 In Vivo
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 In Vitro
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Source

  • 7.1 Murine
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Chimeric
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Humanized
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Human
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Indication

  • 8.1 Cancer
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Autoimmune Diseases
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Inflammatory Diseases
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Infectious Diseases
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Others
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast

9 Market Breakup by End Use

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Research Institutes
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 AbbVie Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Amgen Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Biogen Inc.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 F. Hoffmann-La Roche AG
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
    • 15.3.5 GSK plc
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
      • 15.3.5.4 SWOT Analysis
    • 15.3.6 Johnson & Johnson
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 Merck KGaA
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Novartis AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Novo Nordisk A/S
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Sanofi S.A.
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
      • 15.3.11.3 Financials
      • 15.3.11.4 SWOT Analysis
    • 15.3.12 Thermo Fisher Scientific Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis